ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

VYGR Voyager Therapeutics Inc

8.81
0.28 (3.28%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Voyager Therapeutics Inc VYGR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.28 3.28% 8.81 23:00:09
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
8.76 8.61 8.92 8.81 8.53
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202415:30GLOBEVoyager Therapeutics to Present Broad Set of Translational..
16/4/202406:00GLOBEVoyager Therapeutics Announces Selection of Development..
26/3/202415:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
13/3/202406:00GLOBEVoyager Therapeutics Announces Appointment of Toby Ferguson..
28/2/202415:01GLOBEVoyager Therapeutics Reports Fourth Quarter and Full Year..
28/2/202415:00EDGAR2Form 8-K - Current report
26/2/202406:00GLOBEVoyager Therapeutics Announces Selection of Gene Therapy..
22/2/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202414:16EDGAR2Form 144 - Report of proposed sale of securities
21/2/202414:13EDGAR2Form 144 - Report of proposed sale of securities
21/2/202406:00GLOBEVoyager Therapeutics Announces Fourth Quarter 2023..
20/2/202414:11EDGAR2Form 144 - Report of proposed sale of securities
20/2/202406:00GLOBEVoyager Therapeutics Reports Robust Preclinical Activity in..
16/2/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202406:00GLOBEVoyager Therapeutics to Present at the Oppenheimer Annual..
19/1/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202415:20EDGAR2Form D - Notice of Exempt Offering of Securities
17/1/202414:33EDGAR2Form 144 - Report of proposed sale of securities
17/1/202414:21EDGAR2Form 144 - Report of proposed sale of securities
08/1/202415:49EDGAR2Form 8-K - Current report
08/1/202415:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/1/202421:45GLOBEVoyager Therapeutics Announces Pricing of Public Offering
04/1/202416:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/1/202415:14GLOBEVoyager Therapeutics Announces Proposed Public Offering
03/1/202406:00GLOBEVoyager Therapeutics to Present at the 42nd Annual J.P...
02/1/202406:46DJNVoyager Therapeutics Shares Leap Premarket on Novartis..
02/1/202406:05EDGAR2Form 8-K - Current report
02/1/202406:00GLOBEVoyager Therapeutics Enters Capsid License Agreement and..
06/12/202306:04EDGAR2Form 8-K - Current report
06/12/202306:00GLOBEVoyager Therapeutics Announces Selection of Development..
06/11/202315:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:01GLOBEVoyager Therapeutics Reports Third Quarter 2023 Financial..
06/11/202315:00EDGAR2Form 8-K - Current report
30/10/202306:00GLOBEVoyager Therapeutics Announces Third Quarter 2023 Conference..
02/10/202315:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202306:00GLOBEVoyager Therapeutics to Present at the Chardan Genetic..
18/9/202315:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/9/202312:57EDGAR2Form 144 - Report of proposed sale of securities
07/9/202315:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
30/8/202306:00GLOBEVoyager Therapeutics to Participate in Upcoming Investor..
16/8/202315:18EDGAR2Form 8-K - Current report
08/8/202315:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
07/8/202307:00GLOBEVoyager Therapeutics Announces Appointment of Beth Shafer as..
03/8/202306:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202306:00EDGAR2Form 8-K - Current report
03/8/202306:00GLOBEVoyager Therapeutics Reports Second Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock